Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases
Abstract
:1. Introduction
2. Methods
2.1. Anthropometric and Cardiovascular Risk Factors Assessment
2.2. IBD Activity Indexes
2.3. Liver Transient Elastography
2.4. Biochemical Evaluation
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Li, L.; Liu, D.W.; Yan, H.Y.; Wang, Z.Y.; Zhao, S.H.; Wang, B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies. Obes. Rev. 2016, 17, 510–519. [Google Scholar] [CrossRef] [PubMed]
- Bellentani, S.; Saccoccio, G.; Masutti, F.; Crocè, L.S.; Brandi, G.; Sasso, F.; Cristanini, G.; Tiribelli, C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132, 112–117. [Google Scholar] [CrossRef]
- Fabbrini, E.; Luecking, C.T.; Love-Gregory, L.; Okunade, A.L.; Yoshino, M.; Fraterrigo, G.; Patterson, B.W.; Klein, S. Physiological Mechanisms of Weight Gain-Induced Steatosis in People With Obesity. Gastroenterology 2016, 150, 79–81. [Google Scholar] [CrossRef]
- Morino, K.; Petersen, K.F.; Shulman, G.I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006, 55, S9–S15. [Google Scholar] [CrossRef]
- Cai, D.; Yuan, M.; Frantz, D.F.; Melendez, P.A.; Hansen, L.; Lee, J.; Shoelson, S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11, 183–190. [Google Scholar] [CrossRef] [PubMed]
- Milić, S.; Lulić, D.; Štimac, D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J. Gastroenterol. 2014, 20, 9330–9337. [Google Scholar] [PubMed]
- Ueki, K.; Kondo, T.; Tseng, Y.H.; Kahn, C.R. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 2004, 101, 10422–10427. [Google Scholar] [CrossRef] [Green Version]
- Glassner, K.; Malaty, H.M.; Abraham, B.P. Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease among Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2017, 23, 998–1003. [Google Scholar] [CrossRef]
- Stranges, S.; Dorn, J.M.; Muti, P.; Freudenheim, J.L.; Farinaro, E.; Russell, M.; Nochajski, T.H.; Trevisan, M. Body fat distribution, relative weight, and liver enzyme levels: A population-based study. Hepatology 2004, 39, 754–763. [Google Scholar] [CrossRef] [Green Version]
- Saroli Palumbo, C.; Restellini, S.; Chao, C.Y.; Aruljothy, A.; Lemieux, C.; Wild, G.; Afif, W.; Lakatos, P.L.; Bitton, A.; Cocciolillo, S.; et al. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflamm. Bowel Dis. 2018, 25, 124–133. [Google Scholar] [CrossRef]
- Ferro, Y.; Carè, I.; Mazza, E.; Provenzano, F.; Colica, C.; Torti, C.; Romeo, S.; Pujia, A.; Montalcini, T. Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. Clin. Mol. Hepatol. 2017, 23, 249–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pujia, A.; Gazzaruso, C.; Ferro, Y.; Mazza, E.; Maurotti, S.; Russo, C.; Lazzaro, V.; Romeo, S.; Montalcini, T. Individuals with Metabolically Healthy Overweight/Obesity Have Higher Fat Utilization than Metabolically Unhealthy Individuals. Nutrients 2016, 8, 2. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention (CDC). Use of cessation methods among smokers aged 16–24 years—United States, 2003. MMWR Morb. Mortal. Wkly. Rep. 2006, 55, 1351–1354. [Google Scholar]
- Montalcini, T.; Gorgone, G.; Federico, D.; Ceravolo, R.; Emanuele, V.; Sesti, G.; Perticone, F.; Pujia, A. Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 368–372. [Google Scholar] [CrossRef] [PubMed]
- Schroeder, K.W.; Tremaine, W.J.; Ilstrup, D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987, 317, 1625–1629. [Google Scholar] [CrossRef] [PubMed]
- D’haens, G.; Sandborn, W.J.; Feagan, B.G.; Geboes, K.; Hanauer, S.B.; Irvine, E.J.; Lémann, M.; Marteau, P.; Rutgeerts, P.; Schölmerich, J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132, 763–766. [Google Scholar] [CrossRef] [PubMed]
- Harvey, R.F.; Bradshaw, J.M. A simple index of Crohn’s-disease activity. Lancet 1980, 1, 514. [Google Scholar] [CrossRef]
- Daperno, M.; D’Haens, G.; Van Assche, G.; Baert, F.; Bulois, P.; Maunoury, V.; Sostegni, R.; Rocca, R.; Pera, A.; Gevers, A. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: The SES-CD. Gastrointest. Endosc. 2004, 60, 505–512. [Google Scholar] [CrossRef]
- Rutgeerts, P.; Geboes, K.; Vantrappen, G.; Beyls, J.; Kerremans, R.; Hiele, M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99, 956–963. [Google Scholar] [CrossRef]
- De Lédinghen, V.; Wong, V.W.; Vergniol, J.; Wong, G.L.; Foucher, J.; Chu, S.H.; Le Bail, B.; Choi, P.C.; Chermak, F.; Yiu, K.K. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®. J. Hepatol. 2012, 56, 833–839. [Google Scholar] [CrossRef]
- Myers, R.P.; Pollett, A.; Kirsch, R.; Pomier-Layrargues, G.; Beaton, M.; Levstik, M.; Duarte-Rojo, A.; Wong, D.; Crotty, P.; Elkashab, M. Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012, 32, 902–910. [Google Scholar] [CrossRef]
- Kim, Y.; Chang, Y.; Cho, Y.K.; Ahn, J.; Shin, H.; Ryu, S. Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2018. [Google Scholar] [CrossRef]
- Marra, F.; Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 2018, 68, 280–295. [Google Scholar] [CrossRef]
- Unger, R.H. The physiology of cellular liporegulation. Ann. Rev. Physiol. 2003, 65, 333–337. [Google Scholar] [CrossRef]
- Unger, R.H.; Orci, L. Lipotoxic diseases of nonadipose tissues in obesity. Int. J. Obes. Relat. Metab. Disord. 2000, 24, S28–S32. [Google Scholar] [CrossRef]
- Unger, R.H.; Zhou, Y.T. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001, 50, S118–S121. [Google Scholar] [CrossRef] [Green Version]
- Unger, R.H. Longevity, lipotoxicity and leptin: The adipocyte defense against feasting and famine. Biochimie 2005, 87, 57–64. [Google Scholar] [CrossRef]
- Nguyen, G.C.; Munsell, M.; Harris, M.L. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm. Bowel Dis. 2008, 14, 1105–1111. [Google Scholar] [CrossRef]
- Nic Suibhne, T.; Raftery, T.C.; McMahon, O.; Walsh, C.; O’morain, C.; O’sullivan, M. High prevalence of overweight and obesity in adults with Crohn’s disease: Associations with disease and lifestyle factors. J. Crohn’s Colitis 2013, 7, e241–e248. [Google Scholar] [CrossRef]
- Lomer, M.C.E.; Cahill, O.; Baschali, A. A multicentre Study of Nutrition Risk Assessment in Adult Patients with Inflammatory Bowel Disease Attending Outpatient Clinics. Ann. Nutr. Metab. 2018, 28, 18–23. [Google Scholar] [CrossRef]
- Nguyen, D.L.; Bechtold, M.L.; Jamal, M.M. National trends and inpatient outcomes of inflammatory bowel disease patients with concomitant chronic liver disease. Scand. J. Gastroenterol. 2014, 49, 1091–1095. [Google Scholar] [CrossRef]
- Lazo, M.; Solga, S.F.; Horska, A.; Bonekamp, S.; Diehl, A.M.; Brancati, F.L.; Wagenknecht, L.E.; Pi-Sunyer, F.X.; Kahn, S.E.; Clark, J.M.; et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010, 33, 2156–2163. [Google Scholar] [CrossRef]
- Promrat, K.; Kleiner, D.E.; Niemeier, H.M.; Jackvony, E.; Kearns, M.; Wands, J.R.; Fava, J.L.; Wing, R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51, 121–129. [Google Scholar] [CrossRef]
- Mancina, R.M.; Spagnuolo, R.; Milano, M.; Brogneri, S.; Morrone, A.; Cosco, C.; Lazzaro, V.; Russo, C.; Ferro, Y.; Pingitore, P.; et al. PNPLA3 148 M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. Inflamm. Bowel Dis. 2015, 22, 134–140. [Google Scholar] [CrossRef]
- De Lédinghen, V.; Vergniol, J.; Foucher, J.; Merrouche, W.; le Bail, B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012, 32, 911–918. [Google Scholar] [CrossRef]
- Lapumnuaypol, K.; Kanjanahattakij, N.; Pisarcik, D.; Thongprayoon, C.; Wijarnpreecha, K.; Cheungpasitporn, W. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: A meta-analysis. Eur. J. Gastroenterol. Hepatol. 2018, 30, 854–860. [Google Scholar] [CrossRef]
- Koller, T.; Galambosova, M.; Filakovska, S.; Kubincova, M.; Hlavaty, T.; Toth, J.; Krajcovicova, A.; Payer, J. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J. Gastroenterol. 2017, 23, 4102–4111. [Google Scholar] [CrossRef]
Variables | Mean ± SD |
---|---|
Age (years) | 44 ± 13 |
IBD duration (years) | 8 ± 7 |
Follow-up time (months) | 48 ± 3 |
HBI | 1.2 ± 1.9 |
MCI | 0.9 ± 1.6 |
SES-CD | 2.5 ± 1.2 |
Rutgeerts score * | 1.5 ± 0.5 |
Weight (Kg) | 71 ± 11 |
BMI (Kg/m2) | 25 ± 3 |
Glucose (mg/dL) | 95 ± 20 |
Insulin (μIU/ml) | 11 ± 6 |
HOMA-IR | 1.6 ± 1.7 |
Total Cholesterol (mg/dL) | 180 ± 44 |
Triglycerides (mg/dL) | 118 ± 70 |
HDL Cholesterol (mg/dL) | 54 ± 17 |
LDL Cholesterol (mg/dL) | 116 ± 33 |
AST (IU/L) | 19 ± 7 |
ALT (IU/L) | 21 ± 16 |
γGT (IU/L) | 24 ± 17 |
Total Bilirubin (mg/dL) | 0.63 ± 0.4 |
CAP score (dB/m) | 237 ± 49 |
IQR (%) | 11 ± 6 |
Liver Stiffness (kPa) | 4.7 ± 1 |
IQR (%) | 12 ± 7 |
Prevalence | |
Gender (Male, %) | 63 |
Smokers (%) | 6 |
Crohn’s disease (%) | 33 |
Ulcerative colitis (%) | 67 |
Overweight/Obesity (%) | 55 |
T2DM (%) | 14 |
CCS (%) | 6 |
antiTNFα (%) | 18 |
5ASA (%) | 93 |
AZA/6-MP (%) | 18 |
Methotrexate (%) | 1 |
Variables | Improved a (n = 16) | Stable b (n = 56) | Worsened c (n = 17) | p-Value | Post-Hoc | |
---|---|---|---|---|---|---|
Age (years) | 42 ± 11 | 45 ± 13 | 45 ± 15 | 0.76 | / | |
IBD duration (years) | 9 ± 6 | 9 ± 7 | 7 ± 5 | 0.72 | / | |
Follow-up time (months) | 48 ± 4 | 47 ± 3 | 48 ± 3 | 0.46 | / | |
HBI baseline | 0 ± 0 | 1.6 ± 2 | 0.8 ± 1.8 | 0.21 | / | |
HBI follow-up | 0.60 ± 1.3 | 1.1 ± 1.9 | 2.0 ± 4.5 | 0.61 | / | |
MCI baseline | 1.3 ± 1.7 | 0.9 ± 1.8 | 0.7 ± 1 | 0.67 | / | |
MCI follow-up | 1.5 ± 2.4 | 0.7 ± 1.8 | 1.8 ± 2.2 | 0.18 | / | |
SES-CD baseline | 4 ± 1 | 2.2 ± 0.8 | 2.4 ± 1 | 0.017 | a vs c 0.03 a vs b 0.005 | |
SES-CD follow-up | 4 ± 1 | 2.2 ± 0.8 | 2.4 ± 1 | 0.017 | a vs c 0.03 a vs b 0.005 | |
Weight baseline (Kg) | 72 ± 8 | 71 ± 11 | 68 ± 10 | 0.52 | / | |
Weight follow-up (Kg) | 71 ± 10 | 73 ± 14 | 73 ± 10 | 0.72 | / | |
Δ Weight (Kg) | −1.0 ± 4 | 2.5 ± 6 | 5.4 ± 5 | 0.009 | a vs c 0.009 | |
BMI baseline (Kg/m2) | 26 ± 3 | 25 ± 3 | 24 ± 3 | 0.33 | / | |
BMI follow-up (Kg/m2) | 25 ± 3 | 26 ± 4 | 27 ± 4 | 0.46 | / | |
Δ BMI (Kg/m2) | −0.8 ± 1 | 0.94 ± 3 | 2.5 ± 3 | 0.002 | a vs c 0.002 | |
Glucose (mg/dL) | 98 ± 20 | 92 ± 18 | 104 ± 24 | 0.20 | / | |
Insulin (μIU/ml) | 13 ± 7 | 10 ± 6 | 10 ± 4 | 0.27 | / | |
HOMA-IR | 1.8 ± 1 | 1.6 ± 2 | 1.5 ± 2 | 0.94 | / | |
Total Cholesterol (mg/dL) | 180 ± 44 | 183 ± 44 | 167 ± 43 | 0.37 | / | |
Triglycerides (mg/dL) | 119 ± 50 | 123 ± 77 | 93 ± 50 | 0.27 | / | |
HDL Cholesterol (mg/dL) | 56 ± 15 | 54 ± 17 | 54 ± 17 | 0.93 | / | |
LDL Cholesterol (mg/dL) | 119 ± 40 | 116 ± 29 | 116 ± 43 | 0.92 | / | |
AST (IU/L) | 22 ± 6 | 19 ± 7 | 20 ± 7 | 0.28 | / | |
ALT (IU/L) | 23 ± 12 | 21 ± 18 | 17 ± 10 | 0.51 | / | |
γGT (IU/L) | 19 ± 7 | 26 ± 19 | 22 ± 19 | 0.30 | / | |
Total Bilirubin (mg/dL) | 0.63 ± 0.4 | 0.65 ± 0.4 | 0.57 ± 0.4 | 0.80 | / | |
CRP (mg/dL) | 3.6 ± 3 | 6.3 ± 14 | 3.9 ± 3 | 0.57 | / | |
CAP score baseline (dB/m) | 257 ± 34 | 236 ± 56 | 220 ± 24 | 0.092 | / | |
CAP score follow-up (dB/m) | 203 ± 33 | 234 ± 54 | 270 ± 21 | <0.001 | a vs c <0.001 b vs c 0.021 | |
Δ CAP (dB/m) | −53 ± 21 | −2.1 ± 18 | 51 ± 36 | <0.001 | a vs b <0.001 a vs c <0.001 b vs c <0.001 | |
Liver Stiffness baseline (kPa) | 4.1 ± 1 | 4.9 ± 1 | 4.7 ± 1 | 0.021 | a vs b 0.021 | |
Liver Stiffness follow-up (kPa) | 4.2 ± 1 | 5.1 ± 1 | 5.5 ± 1 | 0.015 | a vs c 0.018 | |
Δ Stiffness (kPa) | 0.15 ± 1 | 0.21 ± 1 | 0.76 ± 2 | 0.28 | / | |
Prevalence | ||||||
Gender (Male, %) | 75 | 63 | 53 | 0.42 | ||
Smokers (%) | 6 | 5 | 9 | 0.92 | ||
Ulcerative colitis (%) | 69 | 66 | 71 | 0.93 | ||
Overweight/Obesity baseline (%) | 69 | 55 | 41 | 0.28 | ||
Overweight/Obesity follow-up (%) | 50 | 66 | 77 | 0.27 | ||
T2DM (%) | 17 | 9 | 27 | 0.29 | ||
CCS (%) | 6 | 7 | 0 | 0.53 | ||
antiTNFα (%) | 19 | 20 | 12 | 0.75 | ||
5ASA (%) | 94 | 93 | 94 | 0.98 | ||
AZA/6-MP (%) | 31 | 14 | 18 | 0.29 | ||
Methotrexate (%) | 0 | 0 | 6 | 0.12 | ||
Liver fibrosis (%) | 0 | 5 | 12 | 0.36 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Spagnuolo, R.; Montalcini, T.; De Bonis, D.; Ferro, Y.; Cosco, C.; Mazza, E.; Romeo, S.; Doldo, P.; Pujia, A. Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients 2019, 11, 303. https://doi.org/10.3390/nu11020303
Spagnuolo R, Montalcini T, De Bonis D, Ferro Y, Cosco C, Mazza E, Romeo S, Doldo P, Pujia A. Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients. 2019; 11(2):303. https://doi.org/10.3390/nu11020303
Chicago/Turabian StyleSpagnuolo, Rocco, Tiziana Montalcini, Daniele De Bonis, Yvelise Ferro, Cristina Cosco, Elisa Mazza, Stefano Romeo, Patrizia Doldo, and Arturo Pujia. 2019. "Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases" Nutrients 11, no. 2: 303. https://doi.org/10.3390/nu11020303
APA StyleSpagnuolo, R., Montalcini, T., De Bonis, D., Ferro, Y., Cosco, C., Mazza, E., Romeo, S., Doldo, P., & Pujia, A. (2019). Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients, 11(2), 303. https://doi.org/10.3390/nu11020303